Diaphragmatic Kinesio Taping With HIIT in Trained Individuals (NCT07390721) | Clinical Trial Compass
RecruitingNot Applicable
Diaphragmatic Kinesio Taping With HIIT in Trained Individuals
Turkey (Türkiye)30 participantsStarted 2025-09-01
Plain-language summary
This study examines whether adding diaphragmatic kinesio taping to high-intensity interval training (HIIT) improves physical performance in trained individuals. Participants will be randomly assigned to one of two groups. One group will perform an 8-week HIIT program on a cycle ergometer. The other group will follow the same HIIT program and will also receive diaphragmatic kinesio taping before each exercise session. The taping is applied to support breathing muscles and may help improve oxygen use during exercise.
Before and after the training period, participants will undergo tests to measure aerobic capacity (VO₂max), anaerobic power (Wingate test), balance (Y-Balance test), lung function (spirometry), body composition, and heart rate responses. The results of this study will help determine whether diaphragmatic kinesio taping provides additional benefits when combined with HIIT training.
Who can participate
Age range
18 Years – 35 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Aged 18-35 years
* Male or female trained individuals
* At least 6 months of regular training history
* Training at least 3-5 days per week
* Estimated VO₂max ≥ 50 ml/kg/min
* No known contraindication to high-intensity exercise
* No allergy or skin condition preventing kinesio taping
* Able to provide written informed consent
Exclusion Criteria:
* History of cardiovascular, respiratory, or metabolic disease (e.g., asthma, COPD, diabetes, heart disease)
* Major musculoskeletal injury or surgery within the past 6 months
* Any pathology affecting diaphragm or respiratory muscles
* Active smoking or substance abuse
* Use of performance-enhancing drugs
* Skin disease in the abdominal region
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Aerobic Capacity (VO₂max)
Timeframe: From baseline to the end of the 8-week intervention